UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993
This article was originally published in The Tan Sheet
Executive Summary
UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993 pending approval from FDA. Motrin IB Sinus would be the first symptom-specific product in the Motrin IB line. Upjohn currently markets Motrin IB (ibuprofen) caplets and tablets. The company is understood to be seeking a number of indications for Motrin IB Sinus including pain relief, fever reduction and nasal decongestion. The product will contain ibuprofen 200 mg and pseudoephedrine 30 mg. Other products on the market with the ibuprofen/pseudoephedrine combination include Whitehall's Advil Cold & Sinus and Dristan Sinus and Robins' Dimetapp Sinus. Upjohn anticipates that Motrin IB Sinus, if cleared, will be offered in both coated caplets and coated tablets. The ad agency of record for the existing Motrin IB line is Southfield, Mich.- based W. B. Doner & Company.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning